Freiman T M, Kukolja J, Heinemeyer J, Eckhardt K, Aranda H, Rominger A, Dooley D J, Zentner J, Feuerstein T J
Sektion Klinische Neuropharmakologie der Neurologischen Universitätsklinik, Neurozentrum, Freiburg, Germany.
Naunyn Schmiedebergs Arch Pharmacol. 2001 May;363(5):537-42. doi: 10.1007/s002100100408.
To elucidate the mechanism of action of the anticonvulsant gabapentin (GBP), we compared its effects on K+-evoked [3H]-noradrenaline ([3H]-NA) release from rat hippocampal and human neocortical slices with those of the KATP channel opener pinacidil and the Na+ channel blockers phenytoin, carbamazepine and lamotrigine. Rat hippocampal and human neocortical slices were loaded with [3H]-NA and superfused. [3H]-NA release was evoked by increasing the extracellular [K+] from 3 to 15 mM. GBP decreased [3H]-NA release from rat hippocampal with a pIC50 of 5.59 and a maximum inhibition of 44%. Concentration-dependent inhibition was also seen in human neocortical slices (39% inhibition with 100 microM GBP). These inhibitory effects were antagonized by the KATP channel antagonist glibenclamide, yielding a pA2 of 7.50 in the rat. The KATP channel opener pinacidil (10 microM), like GBP, decreased [3H]-NA release from rat hippocampal slices by 27% and this effect was also antagonized by glibenclamide. In human neocortical slices the inhibition by pinacidil (10 microM) was 31%. Although phenytoin (10 microM), carbamazepine (100 microM) and lamotrigine (10 microM) also decreased [3H]-NA release (by 25%, 57% and 22%, respectively), glibenclamide did not antagonize the effects of these classical Na+ channel blockers. These findings suggest that GBP inhibits K+-evoked [3H]-NA release through activation of KATP channels. To establish whether the KATP channels under investigation were located on noradrenergic nerve terminals or on other neuronal elements, the effects of GBP were compared in the absence and in the presence of tetrodotoxin (TTX 0.32 microM) throughout superfusion. Since the functional elimination of the perikarya of interneurons by TTX reduced the inhibitory effect of GBP, the KATP channels mediating the effect of GBP may be located on nerve terminals, probably on both noradrenergic and glutamatergic nerve endings.
为阐明抗惊厥药加巴喷丁(GBP)的作用机制,我们将其对大鼠海马体和人类新皮质切片中钾离子诱发的[3H] - 去甲肾上腺素([3H] - NA)释放的影响,与钾离子通道开放剂吡那地尔以及钠离子通道阻滞剂苯妥英、卡马西平和拉莫三嗪的影响进行了比较。将大鼠海马体和人类新皮质切片用[3H] - NA标记并进行灌流。通过将细胞外钾离子浓度从3 mM提高到15 mM来诱发[3H] - NA释放。GBP可降低大鼠海马体中[3H] - NA的释放,其pIC50为5.59,最大抑制率为44%。在人类新皮质切片中也观察到了浓度依赖性抑制作用(100 microM GBP时抑制率为39%)。这些抑制作用被钾离子通道拮抗剂格列本脲拮抗,在大鼠中的pA2为7.50。钾离子通道开放剂吡那地尔(10 microM)与GBP一样,可使大鼠海马体切片中[3H] - NA的释放减少27%,且该作用也被格列本脲拮抗。在人类新皮质切片中,吡那地尔(10 microM)的抑制率为31%。虽然苯妥英(10 microM)、卡马西平(100 microM)和拉莫三嗪(10 microM)也可降低[3H] - NA的释放(分别降低25%、57%和22%),但格列本脲并未拮抗这些经典钠离子通道阻滞剂的作用。这些发现表明,GBP通过激活钾离子通道来抑制钾离子诱发的[3H] - NA释放。为确定所研究的钾离子通道是位于去甲肾上腺素能神经末梢还是其他神经元成分上,在整个灌流过程中,比较了有无河豚毒素(TTX 0.32 microM)时GBP的作用。由于TTX功能性消除中间神经元的胞体降低了GBP的抑制作用,介导GBP作用的钾离子通道可能位于神经末梢,可能同时存在于去甲肾上腺素能和谷氨酸能神经末梢上。